



International Journal of Chemistry and Pharmaceutical Sciences

Journal Home Page: www.pharmaresearchlibrary.com/ijcps



Research Article

Open Access

Antimony chloride immobilized on neutral alumina: an efficient catalyst for the solvent-free selective synthesis of 2-substituted benzoxazoles

K.P.V. Subba Rao, P. Thriveni*, M. Hari Krishna

Department of Chemistry, Vikrama Simhapuri University, Nellore-524001, A.P, India.

ABSTRACT

Synthesis of 2-substituted benzoxazoles from 2-amino phenol and aromatic aldehydes in an excellent yield using $SbCl_3-Al_2O_3$ as catalyst with microwave (MW) irradiation under solvent-free conditions. The present methodology shows some advantages such as short reaction times and enhanced selectivity under solvent-free conditions.

Keywords: Benzoxazoles, microwave, Lewis acid, selectivity

ARTICLE INFO

CONTENTS

| | |
|------------------------------------|-----|
| 1. Introduction | 530 |
| 2. Materials and Method. | 531 |
| 3. Results and Discussion. | 532 |
| 4. Conclusion. | 533 |
| 5. Acknowledgement. | 533 |
| 6. References | 533 |

Article History: Received 05 August 2016, Accepted 21 September 2016, Available Online 27 October 2016

*Corresponding Author

P. Thriveni
Department of Chemistry,
Vikrama Simhapuri University,
Nellore-524001, A.P, India.
Manuscript ID: IJCPS3238



PAPER-QR CODE

Citation: P. Thriveni, et al. Highly efficient one-pot, three-component synthesis of 1, 5-benzodiazepine derivatives using silver triflate as a catalyst. *Int. J. Chem, Pharm, Sci.*, 2016, 4(10): 530-533.

Copyright© 2016 P. Thriveni, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Benzoxazoles [1] are an important class of heterocyclic compounds in which a benzene fused oxazole ring structure. Benzoxazole finds use in research as a starting material for the synthesis of larger, usually bioactive structures. Its aromaticity makes it relatively stable, although as a heterocyclic, it has reactivitiesites which allow for functionalization. The benzoxazole and their derivatives

exhibit wide range of biological activities such as antifungal [2], antihistaminic [3], cyclooxygenase inhibiting [4], antitumor [5], anticonvulsant [7], hypoglycaemic [8], anti-ulcer [6], inflammatory [9,10] and cytotoxic activity [11,12], potential activity with lower toxicities in the chemotherapeutic approach in man [13,14]. Oxazole and its derivatives are used as building block for biochemicals and

pharmaceutical as well as in other industrial applications such as pesticides, dyes, fluorescent brightening agents. The synthesis of 1,3-oxazole derivatives are of much interest because of their diverse pharmaceutical applications and interesting chemical properties. 2-substituted benzoxazoles were synthesized mainly in two methods. One is the coupling of o-substituted amino aromatics with carboxylic acid derivatives by using strong acids or microwave conditions. The other is the oxidative cyclization of Phenolic Schiff bases and aldehydes. Different catalysts were also reported for the synthesis of benzoxazole like Pd(OAc)₂ [15], ZrOCl₂.8H₂O [16], silica sulfuric acid [17], silicasupported Silicasupported sodium hydrogen sulfate [18], Indion 190 resin [19], ([Hbim]BF₄) [20], ethanesulphonic acid [21], Cu(OTf)₂ [22], copper(II) oxide nanoparticles [23], PCC-supported silica gel [24], In(OTf)₃ [25], SnCl₂ [26], DDQ [27], BF₃.OEt₂ [28], Mn(OAc)₃ [29], PhI(OAc)₂ [30], Th⁺.ClO₄⁻ [31], BaMnO₄ [32], NiO₂ [33], and Pb(OAc)₄ [34]. However there are still some limitations with the existing protocols such as drastic reaction conditions, tedious work-up procedures, poor selectivity, low yields, excess amounts of reagent, use of toxic solvents. Therefore, we wished to explore the usage of SbCl₃/Al₂O₃ for the selective synthesis of 2-substituted benzoxazoles by the application of MW technology which shows short reaction times and enhanced selectivity under solvent-free conditions.

2. Materials and Methods

Melting points were measured by using the capillary tube method with an electrothermal method 9200 apparatus. ¹H NMR spectra were recorded on BRUKER ADVANCE II 400 NMR Spectrometer using TMS as internal standard. Chemical shifts are given in ppm () and are referenced to the residual proton resonances of the solvents. Proton and carbon magnetic resonance spectra (¹H NMR and ¹³C NMR) were recorded using tetramethylsilane (TMS) in the solvent of CDCl₃-d or DMSO-d₆ as the internal standard (¹H NMR: TMS at 0.00 ppm, CDCl₃ at 7.26 ppm, DMSO at 2.50 ppm; ¹³C NMR: CDCl₃ at 77.16 ppm, DMSO at 40.00 ppm). The mass spectra were obtained on a JEOL 5x102/DA-6000 mass spectrometer. The IR spectra were recorded on Perkin-Elmer spectrum RX IFT-IR System using KBr pellets.

General procedure for the synthesis of benzoxazoles

(3a-h): Freshly distilled aromatic aldehyde (20 mmol), 2-amino phenol (10 mmol) and 3.1 g of catalyst (5 mol% with respect to SbCl₃) were mixed thoroughly in a beaker and then irradiated in the MW oven for about 10 min at power level 800 W with 30 sec pause after every one min. Upon completion of the reaction (TLC), the reaction mixture was cooled at rt, ethyl acetate (100 ml) was added, and stirred well followed by filtration through celite under suction. The organic layer was washed with water (2 × 30 ml) and brine (30 ml). After drying over anhydrous Na₂SO₄, the solvent was evaporated under reduced pressure and the residue upon column chromatography affords the pure product.

Spectral data for selected compounds:

2-phenyl benzoxazole (3a): yield 93%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.29-8.27 (m, 2H), 7.82-7.78

(m, 1H), 7.62-7.58 (m, 1H), 7.56-7.53 (m, 3H), 7.39-7.35 (m, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): 163.0, 150.7, 142.0, 131.5, 128.9, 127.6, 127.1, 125.1, 124.6, 120.0, 110.6 ppm.

2-(4-fluorophenyl)benzoxazole (3b):

Yielded 90%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.30-8.25 (m, 2H), 7.80-7.76 (m, 1H), 7.60-7.57 (m, 1H), 7.39-7.35 (m, 2H), 7.25-7.20 (m, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): 166.1, 163.5, 162.1, 150.7, 142.0, 129.9 (d, *J* = 9.0 Hz), 125.1, 124.7, 123.5 (d, *J* = 3.0 Hz), 120.0, 116.2 (d, *J* = 22.0 Hz), 110.6 ppm.

2-(4-chlorophenyl)benzoxazole (3c):

Yield 91%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.20 (d, *J* = 8.4 Hz, 2H), 7.79-7.76 (m, 1H), 7.60-7.58 (m, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.40-7.36 (m, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): 162.1, 150.8, 142.1, 137.8, 129.3, 128.9, 125.7, 125.4, 124.8, 120.2, 110 ppm.

2-(4-bromophenyl)benzoxazole (3d):

Yield 90%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.12 (d, *J* = 7.2 Hz, 2H), 7.80-7.75 (m, 1H), 7.66 (d, *J* = 8.8 Hz, 2H), 7.60-7.56 (m, 1H), 7.39-7.35 (m, 2H). ppm. ¹³C NMR (100 MHz, CDCl₃): 162.1, 150.7, 142.0, 132.2, 129.0, 128.9, 126.2, 126.1, 125.4, 125.1, 124.7, 120.1, 120.0, 110.6 ppm

2-(3-chlorophenyl)benzoxazole (3e):

Yield 84%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.26 (d, *J* = 2.0 Hz, 1H), 8.16-8.13 (m, 1H), 7.81-7.77 (m, 1H), 7.62-7.57 (m, 1H), 7.52-7.50 (d, *J* = 8.4 Hz, 2H), 7.40-7.36 (m, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): 161.6, 150.7, 141.9, 135.0, 131.5, 130.2, 128.8, 127.6, 125.6, 125.5, 124.8, 120.2, 110.7 ppm.

2-(3-methoxyphenyl)benzoxazole (3f):

Yielded 86%, white solid. ¹H NMR (400 MHz, CDCl₃): 7.87 (d, *J* = 8.0 Hz, 1H), 7.81-7.79 (m, 2H), 7.62-7.59 (m, 1H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.40-7.35 (m, 2H), 7.12-7.09 (m, 2H), 3.94 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): 162.9, 159.9, 150.7, 142.0, 130.0, 128.3, 125.2, 124.6, 120.1, 120.0, 118.4, 111.8, 110.6, 55.5 ppm.

2-(p-tolyl)benzoxazole (3g):

Yield 92%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.16 (d, *J* = 8.4 Hz, 2H), 7.78-7.76 (m, 1H), 7.59-7.57 (m, 1H), 7.36-7.33 (m, 4H), 2.45 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): 163.3, 150.7, 142.1, 129.6, 127.6, 124.9, 124.5, 124.3, 119.8, 110.5, 21.7 ppm.

2-(4-(trifluoromethyl) phenyl)benzoxazole (3h):

Yield 90%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.39 (d, *J* = 8.0 Hz, 2H), 7.84-7.79 (m, 3H), 7.64-7.60 (m, 1H), 7.44-7.38 (m, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): 161.5, 150.8, 141.9, 133.1, 132.8, 130.4, 127.8, 126.0, 125.9, 125.9, 125.8, 125.1, 124.9, 122.4, 120.4, 110.8 ppm.

2-(4-methoxyphenyl)benzoxazole (3i):

Yield 93%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.21 (d, *J* = 8.8 Hz, 2H), 7.76-7.73 (m, 1H), 7.57-7.55 (m, 1H), 7.36-7.30 (m, 2H), 7.03 (d, *J* = 8.4 Hz, 2H), 3.90 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): 163.1, 162.3, 150.6, 142.2, 129.3, 124.6, 124.4, 119.7, 119.6, 114.3, 110.3, 55.4 ppm.

4-(benzoxazol-2-yl)benzonitrile (3j):


Yield 89%, white solid. ¹H NMR (400 MHz, CDCl₃): 8.38 (d, *J* = 8.8 Hz, 2H), 7.85-7.82 (m, 3H), 7.65-7.62 (m,

1H), 7.46-7.40 (m, 2H).ppm. ¹³C NMR (100 MHz, CDCl₃): 160.9, 150.9, 141.8, 132.7, 131.1, 127.9, 126.2, 125.1, 120.6, 118.2, 114.7, 110.9 ppm.

3. Results and Discussion

In our preliminary investigation on the model reaction of 2-amino phenol and benzaldehyde, it was found that the reaction could be finished under very simple reaction conditions in the presence of SbCl₃/Al₂O₃, which gives the desired benzoxazole product in good yield (Scheme 1). In order to investigate the scope of the reaction, different substituted aldehydes were employed and the results are summarized in Table 1. The optimized reaction conditions for the reaction were found to be SbCl₃/Al₂O₃ under room temperature. SbCl₃/Al₂O₃ have proved to be an effective catalyst for the synthesis of various 2-substituted-1,3-benzoxazoles and yield is affected by the position of the substituent on aromatic ring of the aldehydes. Meta-

substituted aryl aldehyde (3e, 3f), the yield was lower than that when para-substituted aryl aldehydes were used. Also, the results found in Table 1(3d, 3e, 3f) may indicate that the yield is dependent on the electronic nature of the substituent as well.



Scheme 1: Synthesis of 2-substituted benzoxazoles from 2-aminophenol and aldehydes

Table 1: Synthesis of 2-substituted benzoxazoles from 2-aminophenol and aldehydes

| Entry | Aldehydes | Product | Yield (%) |
|-------|-----------|---------|-----------|
| 1 | | | 93 |
| 2 | | | 90 |
| 3 | | | 91 |
| 4 | | | 90 |
| 5 | | | 84 |
| 6 | | | 86 |
| 7 | | | 92 |
| 8 | | | 90 |
| 9 | | | 93 |
| 10 | | | 89 |

4. Conclusion

In conclusion, we have demonstrated that 2-substituted benzoxazoles can be synthesized from 2-aminophenols and aldehydes in the presence of $\text{SbCl}_3/\text{Al}_2\text{O}_3$ in good yields. The present protocol is very simple and shows specific advantages, enhanced selectivity under solvent-free conditions and an alternative route to benzoxazole synthesis using 2-aminophenols and aldehydes.

5. Acknowledgment

Authors are thankful to our Research Supervisor Dr. P. Thrivani for providing us required facilities and motivation for completion of the research work. We also extend our gratitude towards BRNS, BARC, Mumbai for financial assistance and ICT, Hyderabad for providing us facilities of IR Spectra, ^1H NMR for characterization of synthesized compounds

6. References

- [1] M. O. Chaney, P. V. Demarco, N. D. Jones, J. L. Occolowitz, *J. Am. Chem. Soc.* **1974**, 96, 1932–1933.
- [2] T. Kusumi, T. Ooi, M. R. Walchli, H. Kakisawa. *J. Am. Chem. Soc.* **1988**, 110, 2954–2958.
- [3] A. D. Rodriguez, C. Ramirez, I. I. Rodriguez. *Org. Lett.* **1999**, 1, 527–530.
- [4] Y. Kastura, Y. Tnoue, S. Nishino. *Chem. Pharm. Bull.* **1992**, 40(6), 1424.
- [5] Y. Ismail, O. Ikay, T. Özlem. *Acta Biochimica Polonica.* **2000**, 47, 481–486.
- [6] R. Shrinivasa, P. Rao, P. Kumar. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 657–660.
- [7] S. Aiello, G. Wells, E. Ston, H. Kadri. *J. Med. Chem.* **2008**, 51, 5135–5139.
- [8] Y. Kastura, Y. Tnoue, S. Nishino, *Chem. Pharm. Bull.*, **1992**, 40(6), 1424–1438.
- [9] N. Siddiqui, M. Sarafaroz, M. Alam, W. Ahsan. *Acta Poloniae Pharmaceutica-Drug Res.* **2008**, 65(4), 449–455.
- [10] K. Arakova, M. Inamasu, M. Masumoto, *Chem. Pharm. Bull.* **1997**, 45(12), 1984.
- [11] S. Sondhi, N. Singh, A. Kumar, O. Lozach, *Bioorg. Med. Chem.* **2006**, 14(11), 3758–3765.
- [12] S. S. Unlu, Kupeli E. Baytas, *Archives Der Pharmazie*, **2003**, 336, 6, 310.
- [13] N. N. Eshbha, H. M. Dalama, *Pharmazie*, **1985**, 40, 320.
- [14] Venkateshwar Rao J, Sarangapani M, *Int. J. Chem. Sci.* **2007**, 5(5), 2161–2168.
- [15] R.D. Haugwitz, R.G. Angel, V.L. Narayanan. *J. Med. Chem.* **1982**, 25, 969.
- [16] T. Hisano, M. Ichikawa, M. Tasaki, *Chem. Pharm. Bull.* **1982**, 30, 2996.
- [17] Baltork I.M, Moghadam, M, Tangestaninejad S, Mirkhani V, Zolfigol M.A, Hojati, S.F. *J. Iran. Chem. Soc.* **2008**, 5, 65–70.
- [18] Ravi Kumar K, Satyanarayana P.V.V, Srinivasareddy B. *Der Pharma. Chemica.* **2012**, 4, 761–766.
- [19] Baltork I.M, Khosropour, A.R. *Catal. Commun.* **2007**, 8, 1865–1870.
- [20] Pang, Y, Hua, W. *Tetrahedron Lett.* **2009**, 50, 6680–6683.
- [21] Padalkar V.S, Gupta V.D, Phatangare K.R, Patil V.S, Umape P.G, Sekar N. *Green Chem. Lett. Rev.* **2012**, 5 (2), 139–145.
- [22] Nadaf R.N, Siddiqui S.A, Daniel T, Lahoti R.J, Srinivasan K.V. *J. Mol. Catal. A Chem.* **2004**, 214, 155–159.
- [23] Kumar D, Rudrawar S, Chakraborti A.K. *Aust. J. Chem.* **2008**, 61, 881–887.
- [24] Guru M.M, Ali M.A, Punniyamurthy T. *Org. Lett.* **2011**, 13, 1194–1197.
- [25] Saha P, Ramana T, Purkait N, Ali M.A, Paul R, Punniyamurthy T. *J. Org. Chem.* **2009**, 74, 8719–8725.
- [26] Praveen C, Kumar K.H, Muralidharan D, Perumal P.T. *Tetrahedron.* **2008**, 64, 2369–2374.
- [27] Wang B, Zhang Y, Li P, Wang L. *Chin. J. Chem.* **2010**, 28, 1697–1703.
- [28] Cho C.S, Kim D.T, Zhang J.Q, Ho S.L.J. *Heterocyclic Chem.* **2002**, 39, 421–423.
- [29] Chang J, Zhao K, Pan S. *Tetrahedron Lett.* **2002**, 43, 951–954.
- [30] Nagawade R.R, Shinde D.B. *Chin. Chem. Lett.* **2006**, 17, 453–456.
- [31] Varma R.S, Kumar D. *J. Heterocycl. Chem.* **1998**, 35, 1539–1540.
- [32] Varma R.S, Saini R.K, Prakash O. *Tetrahedron Lett.* **1997**, 38, 2621–2622.
- [33] Park K.H, Jun K, Shin S.R, Oh S.W. *Tetrahedron Lett.* **1996**, 37, 8869–8870.
- [34] Srivastava R.G, Venkataramani P.S. *Synth. Commun.* **1988**, 18, 1537–1544.
- [35] Nakagawa K.; Onoue H, Sugita. *J. Chem. Pharm. Bull.* **1964**, 12, 1135–1138.
- [36] Stephens F.F, Bower J.D. *J. Chem. Soc.* **1949**, 12, 2971–2972.